The U.S. five-year cancer survival rate reached 70% in 2025, creating 18.6 million survivors. Health systems are expanding survivorship care using advanced practice providers and investing over $4 billion in oncology infrastructure to meet growing demand.
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601100 |
Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07592910 |
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07569250 |
Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization |
NOT_YET_RECRUITING | NA |
| NCT07563010 |
Menin-Inhibitor Targeted Maintenance in AML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07562399 |
Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda |
NOT_YET_RECRUITING | NA |
| NCT07551635 |
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07548476 |
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy |
NOT_YET_RECRUITING | NA |
| NCT07519200 |
Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention |
NOT_YET_RECRUITING | NA |
| NCT07517666 |
Genetic Information for Families After Tumor Testing Study |
ENROLLING_BY_INVITATION | NA |
| NCT07516405 |
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults |
RECRUITING | PHASE1 |
